First of all, compound semaglutide is not FDA-approved
Common mold toxicity symptom patterns may include: Chronic respiratory irritation, including congestion or wheezing Persistent eye, skin, or throat irritation Fluctuating allergy-type symptoms poorly responsive to standard treatment Systemic patterns often associated with chronic mold exposure include: Brain fog and impaired concentration Persistent fatigue or non-restorative sleep Mood changes or sleep disruption Balance disturbances or dizziness Recurrent fungal or yeast-related patterns Digestive disruption Heightened sensory sensitivity (light, sound, chemicals, foods) Neurological sensations such as tingling, tremors, or headaches Because these symptoms overlap with chronic fatigue syndromes, fibromyalgia, anxiety disorders, irritable bowel patterns, and autoimmune dysregulation, mold toxicity is frequently overlooked without environmental context
GSH-px, which was lower than in non-MS controls before the start of treatment, increased fivefold during 5 wk of treatment
Most peptide evidence comes from animal models, small studies, and mechanistic extrapolation
The White House recently announced a landmark deal with pharmaceutical companies Eli Lilly and Nordisk that will impact Medicare beneficiaries and others in the coming months